HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Amantadine for dyskinesia in patients affected by severe Parkinson's disease.

Abstract
20 patients (12 men and 8 women, mean age 65 years) affected by severe Parkinson's disease (PD) with peak-dose and/or diphasic dyskinesias or painful dyskinesia were treated with amantadine (300 mg/day) as adjunctive therapy to current levodopa, carbidopa and dopaminoagonist. UPDRS (Unified Parkinson's disease rating scale), dyskinesias rating scale (DRS) and IGA (investigator global assessment) scale were used to evaluate the severity of PD symptoms during follow-up. After 15 days with amantadine treatment all patients improved with an average 38% reduction in dyskinesias (p<0.001). After 2-8 months. amantadine was withdrawn in all patients. After amantadine withdrawal, 2 patients experienced severe hyperthermia (39 degrees C and 40 degrees C). No difference was found between end of treatment dyskinesia scores and final withdrawal scores (p<0.5). In the two patients with hyperthemia amantadine was reintroduced; after four days hyperthermia subsided and amantadine was finally tapered over 15 days without further adverse reactions.
AuthorsC Paci, A Thomas, M Onofrj
JournalNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (Neurol Sci) Vol. 22 Issue 1 Pg. 75-6 (Feb 2001) ISSN: 1590-1874 [Print] Italy
PMID11487209 (Publication Type: Clinical Trial, Journal Article)
Chemical References
  • Antiviral Agents
  • Dopamine Agents
  • Levodopa
  • Amantadine
Topics
  • Aged
  • Amantadine (adverse effects, therapeutic use)
  • Antiviral Agents (adverse effects, therapeutic use)
  • Disease Progression
  • Dopamine Agents (adverse effects)
  • Drug Administration Schedule
  • Drug Interactions (physiology)
  • Drug Therapy, Combination
  • Dyskinesia, Drug-Induced (drug therapy, physiopathology)
  • Female
  • Humans
  • Levodopa (adverse effects)
  • Male
  • Middle Aged
  • Parkinson Disease (drug therapy, physiopathology)
  • Recovery of Function (drug effects, physiology)
  • Substance Withdrawal Syndrome (physiopathology)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Research Interface PRO additionally includes drill-down to evidence, articles by author, export to Excel, FDA Link and mobile subscription:
1 year subscription, $490.00 USD